Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) protein degradation technology. The company operates within the biopharmaceutical and biotechnology industries, with a primary emphasis on oncology and other serious diseases driven by pathogenic proteins that have historically been difficult to target with traditional small-molecule drugs.
Arvinas was founded in 2013 based on research from Yale University and has since positioned itself as a pioneer in targeted protein degradation. Unlike conventional inhibitors, PROTACs are designed to selectively tag disease-causing proteins for destruction by the cell’s natural protein disposal system. This approach is intended to address limitations of existing therapies, including drug resistance and incomplete target inhibition, and represents a differentiated strategy within precision medicine.
Business Operations
Arvinas operates as a single-reportable-segment biotechnology company, with revenue historically derived from collaboration agreements, licensing fees, and research funding, rather than product sales. Its core operations center on internal research and development of clinical and preclinical PROTAC candidates, particularly in oncology, alongside selective external partnerships.
The company controls a broad intellectual property portfolio covering its PROTAC platform and therapeutic candidates. Key development programs have included vepdegestrant (ARV-471) for estrogen receptor–positive breast cancer and bavdegalutamide (ARV-110) for metastatic castration-resistant prostate cancer. Arvinas has engaged in strategic collaborations with large pharmaceutical companies, though the structure and scope of these partnerships have evolved over time as programs have advanced or been reprioritized.
Strategic Position & Investments
Arvinas’ strategy centers on advancing wholly owned clinical assets while selectively partnering programs to share development risk and extend global reach. The company continues to invest heavily in expanding the applicability of PROTAC technology beyond oncology, including exploration of other disease-relevant protein targets that are considered “undruggable” by conventional methods.
Strategic investments have primarily taken the form of internal R&D spending rather than acquisitions. While Arvinas has entered into high-profile collaborations with major pharmaceutical companies in the past, certain partnerships have been modified or concluded as clinical data emerged, with Arvinas retaining rights to advance key assets independently. Data inconclusive based on available public sources regarding long-term partnership commitments beyond currently disclosed programs.
Geographic Footprint
Arvinas is headquartered in New Haven, Connecticut, and conducts the majority of its research and corporate operations in the United States. Its proximity to Yale University and major academic research centers has been a strategic advantage in talent recruitment and scientific collaboration.
Internationally, Arvinas’ presence is primarily indirect, achieved through clinical trials and former or current collaborations with global pharmaceutical partners that operate across Europe and Asia-Pacific. The company does not report significant standalone international facilities, but its clinical programs have global reach through multinational trial sites and regulatory engagement.
Leadership & Governance
Arvinas was founded by Craig Crews, a Yale University professor whose academic work laid the foundation for PROTAC technology. The company is led by an executive team with deep experience in drug discovery, clinical development, and biotechnology commercialization, emphasizing scientific rigor and disciplined capital allocation.
- John Houston, PhD – President and Chief Executive Officer
- Noah Berkowitz, MD, PhD – Chief Medical Officer
- Andrew Saik, JD – Chief Operating Officer
- Sean Cassidy – Chief Financial Officer
- Ian Taylor, PhD – Chief Scientific Officer
The leadership team has consistently articulated a strategy focused on long-term value creation through platform innovation, selective pipeline prioritization, and maintaining operational flexibility as clinical data mature.